abstract |
The present disclosure provides compounds represented by Formula (la): and the pharmaceutically acceptable salts thereof, wherein R 1a , R 1b , R 1c , R 2 , R 3 , L, M and G are as defined as set forth in the specification. The present disclosure also provides compounds of Formula la for use to treat a condition or disorder responsive to menin inhibition such as cancer. |